|
Market Closed -
Nasdaq
23:00:00 03/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 34.82 USD | +0.32% |
|
+4.22% | -23.13% |
| 09-03 | Tracelink, Inc. and Omnicell, Inc. Integrate Dscsa Compliance Solution into Hospital Pharmacy Operations | CI |
| 08-14 | US Physical Therapy Names Nchacha Etta as Chief Financial Officer | MT |
Company Valuation: Omnicell, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 7,929 | 2,251 | 1,711 | 2,062 | 2,033 | 1,588 | - | - |
| Change | - | -71.61% | -24% | 20.51% | -1.41% | -21.87% | - | - |
| Enterprise Value (EV) | 8,068 | 2,487 | 1,813 | 2,034 | 2,033 | 1,588 | 1,588 | 1,588 |
| Change | - | -69.17% | -27.13% | 12.18% | -0.03% | -21.87% | 0% | 0% |
| P/E | 111x | 420x | -83.6x | 165x | 1,133x | 35.4x | 34.3x | 22.8x |
| PBR | 6.95x | 2x | 1.43x | 1.66x | - | - | - | - |
| PEG | - | -4.5x | 0x | -1x | -13.3x | 0x | 11x | 0.4x |
| Capitalization / Revenue | 7x | 1.74x | 1.49x | 1.85x | 1.72x | 1.28x | 1.23x | 1.18x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 1.28x | 1.23x | 1.18x |
| EV / EBITDA | 0x | 0x | 0x | 0x | 0x | 8.7x | 8.91x | 7.81x |
| EV / EBIT | 0x | -0x | 0x | 0x | 0x | 12.6x | 13.3x | 11.5x |
| EV / FCF | 0x | 0x | 0x | 0x | 0x | 21.8x | 25x | 21x |
| FCF Yield | 2.56% | 0.76% | 7.37% | 7.34% | 4.27% | 4.58% | 4% | 4.76% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 1.62 | 0.12 | -0.45 | 0.27 | 0.04 | 0.9833 | 1.014 | 1.53 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 1,132 | 1,296 | 1,147 | 1,112 | 1,185 | 1,237 | 1,288 | 1,344 |
| EBITDA 1 | 229.6 | 192.9 | 137.9 | 135.8 | 139.9 | 182.6 | 178.2 | 203.5 |
| EBIT 1 | 89.51 | -2.323 | 81.52 | 78.12 | 83.21 | 126.3 | 119.7 | 138.1 |
| Net income 1 | 77.85 | 5.648 | -20.37 | 12.53 | 2.052 | 45.27 | 47.37 | 72.12 |
| Net Debt | 139.1 | 236.2 | 101.7 | -28.48 | - | - | - | - |
| Reference price 2 | 180.44 | 50.42 | 37.63 | 44.52 | 45.30 | 34.82 | 34.82 | 34.82 |
| Nbr of stocks (in thousands) | 43,943 | 44,650 | 45,469 | 46,317 | 44,877 | 45,615 | - | - |
| Announcement Date | 2/14/22 A | 2/28/23 A | 2/8/24 A | 2/6/25 A | 2/5/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 35.41x | - | - | -.--% | 1.59B | |
| 43.54x | 10.57x | 23.29x | -.--% | 46.04B | |
| 96.33x | 52.41x | 66.54x | 0.55% | 12.98B | |
| 83.88x | 13.21x | 54.01x | 0.68% | 5.87B | |
| -59x | 16.73x | -109.55x | - | 4.32B | |
| -7.01x | 62.67x | -7.1x | - | 2.1B | |
| -127.83x | - | - | - | 1.08B | |
| 6.87x | - | - | - | 1.01B | |
| 115.67x | - | - | 1.15% | 800M | |
| Average | 20.87x | 31.12x | 5.44x | 0.48% | 8.42B | |
| Weighted average by Cap. | 46.12x | 20.31x | 24.74x | 0.18% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- OMCL Stock
- Valuation Omnicell, Inc.
Select your edition
All financial news and data tailored to specific country editions
